Explore

Trendline Trendline
Bayer Acquires Perfuse Therapeutics to Enhance Ophthalmology Pipeline

Bayer Acquires Perfuse Therapeutics to Enhance Ophthalmology Pipeline

Bayer Acquires Perfuse Therapeutics to Enhance Ophthalmology Pipeline
Trendline Trendline
Bayer to Acquire Perfuse Therapeutics in $2.45 Billion Deal to Enhance Ophthalmology Pipeline

Bayer to Acquire Perfuse Therapeutics in $2.45 Billion Deal to Enhance Ophthalmology Pipeline

Bayer to Acquire Perfuse Therapeutics in $2.45 Billion Deal to Enhance Ophthalmology Pipeline
Trendline Trendline
Bayer Acquires Perfuse Therapeutics to Enhance Ophthalmology Portfolio

Bayer Acquires Perfuse Therapeutics to Enhance Ophthalmology Portfolio

Bayer Acquires Perfuse Therapeutics to Enhance Ophthalmology Portfolio
Trendline Trendline
Bayer's $2.45 Billion Acquisition of Perfuse Therapeutics Aims to Revolutionize Eye Disease Treatment

Bayer's $2.45 Billion Acquisition of Perfuse Therapeutics Aims to Revolutionize Eye Disease Treatment

Bayer's $2.45 Billion Acquisition of Perfuse Therapeutics Aims to Revolutionize Eye Disease Treatment
Trendline Trendline
Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment
Trendline Trendline
Thermo Fisher Scientific Launches New Bioreactor for Cell Therapy

Thermo Fisher Scientific Launches New Bioreactor for Cell Therapy

Thermo Fisher Scientific Launches New Bioreactor for Cell Therapy
Trendline Trendline
UCB to Acquire Candid Therapeutics for $2.2 Billion to Enhance TCE Antibody Portfolio

UCB to Acquire Candid Therapeutics for $2.2 Billion to Enhance TCE Antibody Portfolio

UCB to Acquire Candid Therapeutics for $2.2 Billion to Enhance TCE Antibody Portfolio
Trendline Trendline
Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients

Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients

Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients
Trendline Trendline
Sensei Biotherapeutics Begins Phase 1b/2 Trial of PIKTOR for Advanced Breast Cancer

Sensei Biotherapeutics Begins Phase 1b/2 Trial of PIKTOR for Advanced Breast Cancer

Sensei Biotherapeutics Begins Phase 1b/2 Trial of PIKTOR for Advanced Breast Cancer
Trendline Trendline
Thermo Fisher Scientific Launches New Bioreactor for Scalable Cell Therapy Manufacturing

Thermo Fisher Scientific Launches New Bioreactor for Scalable Cell Therapy Manufacturing

Thermo Fisher Scientific Launches New Bioreactor for Scalable Cell Therapy Manufacturing
Trendline Trendline
Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD
Trendline Trendline
Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics